Hematologic Cancer Profiling
Genomic Profiling of Hematologic Malignancies
Blood cancers affect the production and function of blood cells. Most of these cancers start in the bone marrow where blood is produced.
Stem cells in the bone marrow mature and develop into three types of blood cells: red blood cells, white blood cells, or platelets. In most blood cancers, the normal blood cell development process is interrupted by the uncontrolled growth of an abnormal type of blood cell. These abnormal blood cells, or cancerous cells, prevent blood from performing many of its functions, like fighting off infections or preventing serious bleeding.
The many stages of hematopoietic differentiation and abundant opportunities for mutations give rise to a vast phenotypic and genetic heterogeneity of acute and chronic myeloid malignancies.
Versatile Solution for Genomic Profiling of Hematologic Tumors
The hematology community has relied mainly on cytogenetic and single-gene methods in the past. Next-generation sequencing (NGS) provides many benefits over traditional methods, including faster, more scalable, and more sensitive profiling of hematologic tumors.
Amplicon-based targeted sequencing is an ideal approach that is cost-effective and easy to implement in the laboratory. The workflow is fast and simple to carry out, and the approach allows researchers to focus only on genes related to one or more subtypes of hematologic malignancy to control the cost of sequencing.
Obtain Accurate, Reproducible, and Highest-Quality Results from Tumor Samples
CleanPlex Custom NGS Panels are powered by Paragon Genomics’ CleanPlex Technology – an ultra-high multiplex PCR-based target enrichment technology for next-generation sequencing (NGS).